SO SÁNH HIỆU QUẢ CỦA PHÁC ĐỒ EBTT VÀ EBAT TRONG ĐIỀU TRỊ TIỆT TRỪ HELICOBACTER PYLORI

Abstract

Background: Currently, antibiotic resistance of Helicobacter pylori (H.pylori) is increasing in the population. According to the recommendations of the Asia-Pacific region, according to the Maastricht V consensus and the 2016 Toronto consensus, in countries where the prevalence of H.pylori resistant to Clarithromycin and Metronidazole is above 15%, the first 4-drug regimen with Bismuth can be used. and the alternative regimen of choice is PPI-Bismuth-Tinidazole-Amoxicillin with Amoxicillin as an alternative to Tetracycline. In Vietnam, there are currently no studies on the effectiveness of 4-drug regimens containing Tinidazole instead of Metronidazole and Amoxycillin instead of Tetracycline in the 4-drug regimen to initiate H.pylori treatment. Objectives: To determine the eradication rates of 2 regimens EBTT (Esomeprazol-Bismuth-Tinidazole-Tetracycline) and EBAT (Esomeprazol-Bismuth-Tinidazole-Amoxycillin) in the treatment of H.pylori. Methods: A prospective randomized controled study. Patients were treated at gastroenterology clinic of Tam Anh General Hospital with a confirmed diagnosis of H.pylori infection (on endoscopy) from April 2022 to November 2022. Results: Of 158 patients, 86 patients were treated with EBTT regimen and 72 patients were treated with EBAT regimen. The eradication rate of H.pylori with EBTT regimen was 96.5% and EBAT was 83.6%. The most common adverse effects were black stool (25.3%); bitter mouth (11.4%); diarrhea (11.4%); nausea (3.8%); fatigue (2.5%). Conclusion: The eradication rate of H.pylori with EBTT regimen was 96.5% and EBAT was 83.6%. Adverse effects were mild.